GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » Net Income From Continuing Operations

CombiGene AB (OSTO:COMBI) Net Income From Continuing Operations : kr-44.88 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CombiGene AB's net income from continuing operations for the three months ended in Dec. 2024 was kr-14.16 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was kr-44.88 Mil.

CombiGene AB Net Income From Continuing Operations Historical Data

The historical data trend for CombiGene AB's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB Net Income From Continuing Operations Chart

CombiGene AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only -28.16 20.97 -6.95 -38.60 -47.22

CombiGene AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.36 -14.19 -7.57 -8.96 -14.16

CombiGene AB Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-44.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CombiGene AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » Net Income From Continuing Operations
Comparable Companies
OSTO:CMOTEC B OSTO:2CUREX OSTO:MODTX XSAT:CHOSA XSAT:NIDHOG OSTO:SIMRIS B OSTO:ONCOZ OSTO:EXPRS2 OSTO:SPRINT OSTO:ATORX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Agavagen 52A, Lidingo, SWE, SE-181 55
Website
https://www.combigene.com
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB Headlines

No Headlines